Ftse Mib
34.339,32
0,00%
DAX
18.679,71
0,00%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,27%
Bitcoin
63.151,56
0,16%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lipocine Inc (LPCN) Lipocine Inc (LPCN) Notizie

LPCN

Lipocine (LPCN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LPCN
DataOraFonteTitoloSimboloCompagnia
09/05/202414:00PR Newswire (US)Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024NASDAQ:LPCNLipocine Inc
09/05/202412:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPCNLipocine Inc
09/05/202412:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
08/05/202414:00PR Newswire (US)Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024NASDAQ:LPCNLipocine Inc
01/05/202414:00PR Newswire (US)Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154NASDAQ:LPCNLipocine Inc
11/04/202413:00PR Newswire (US)Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityNASDAQ:LPCNLipocine Inc
28/03/202413:00PR Newswire (US)Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisNASDAQ:LPCNLipocine Inc
25/03/202413:00PR Newswire (US)Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
07/03/202414:00PR Newswire (US)Lipocine Announces Financial Results for the Full Year Ended December 31, 2023NASDAQ:LPCNLipocine Inc
07/03/202412:07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LPCNLipocine Inc
06/03/202414:00PR Newswire (US)Lipocine to Present at 36th Annual Roth ConferenceNASDAQ:LPCNLipocine Inc
06/02/202414:00PR Newswire (US)Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
02/02/202414:00PR Newswire (US)Lipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsNASDAQ:LPCNLipocine Inc
18/01/202414:00PR Newswire (US)Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and CanadaNASDAQ:LPCNLipocine Inc
19/12/202314:00PR Newswire (US)Lipocine to Present at Biotech Showcase 2024NASDAQ:LPCNLipocine Inc
22/11/202322:15Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LPCNLipocine Inc
13/11/202320:45PR Newswire (US)Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023NASDAQ:LPCNLipocine Inc
08/11/202314:00PR Newswire (US)Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023NASDAQ:LPCNLipocine Inc
01/11/202313:00PR Newswire (US)Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023NASDAQ:LPCNLipocine Inc
26/10/202314:00PR Newswire (US)Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum DepressionNASDAQ:LPCNLipocine Inc
24/10/202301:00PR Newswire (US)Lipocine to Present at the H.C. Wainwright Annual NASH Investor ConferenceNASDAQ:LPCNLipocine Inc
19/09/202322:05PR Newswire (US)Lipocine to Present at the Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:LPCNLipocine Inc
10/08/202314:00PR Newswire (US)Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023NASDAQ:LPCNLipocine Inc
27/07/202312:30PR Newswire (US)LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with CirrhosisNASDAQ:LPCNLipocine Inc
26/06/202315:21Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LPCNLipocine Inc
14/06/202314:00PR Newswire (US)Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual ConferenceNASDAQ:LPCNLipocine Inc
07/06/202314:00PR Newswire (US)Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023NASDAQ:LPCNLipocine Inc
25/05/202321:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LPCNLipocine Inc
16/05/202313:00PR Newswire (US)Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of DepressionNASDAQ:LPCNLipocine Inc
11/05/202312:00PR Newswire (US)Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023NASDAQ:LPCNLipocine Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LPCN

La tua Cronologia

BIT
11COV
Covestro
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network